<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940328-0-00012</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> March 28, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 522</CFRNO> <!-- PJG 0012 frnewline --> Implantation or Injectable Dosage Form New Animal Drugs; Xylazine Injection <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Fort Dodge Laboratories, Inc. The ANADA provides for intravenous and intramuscular use in horses and intramuscular use in  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> Cervidae <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  spp. of xylazine injection to produce sedation accompanied by a shorter period of analgesia. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> March 28, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Charles W. Francis, Center For Veterinary Medicine (HFV&hyph;114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1617. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Fort Dodge Laboratories, Inc. (Fort Dodge), P.O. Box 518, Fort Dodge, IA 50501, filed ANADA 200&hyph;088 which provides for intravenous and intramuscular use in horses and intramuscular use in  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> Cervidae <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  spp. (fallow deer, mule deer, Sika deer, white-tailed deer, and elk) of Sedazine <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=5 f=1 --> TM <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  (xylazine 100 milligrams per milliliter (mg/mL)) injectable to produce sedation accompanied by a shorter period of analgesia. The drug is limited to use by or on the order of a licensed veterinarian. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ANADA 200&hyph;088 for Fort Dodge's Sedazine <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> TM <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (xylazine 100 mg/mL) injectable is as a generic copy of Miles' new animal drug application (NADA 047&hyph;956) for Rompun <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (xylazine 100 mg/mL) injectable. The ANADA is approved as of February 24, 1994, and the regulations are amended in 21 CFR 522.2662 to reflect the approval. The basis for approval is discussed in the freedom of information summary. <!-- PJG 0012 frnewline --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 522  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 522_IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 522 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 522.2662 is amended in paragraph (b) by adding a new sentence after the paragraph heading to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;522.2662  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Xylazine hydrochloride injection. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sponsor <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See No. 000856 in &sect;510.600(c) of this chapter for use in horses, wild deer, and elk. * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: March 21, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FURTHER> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Richard H. Teske, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;7201 Filed 3&hyph;25&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            